Pular para o conteúdo
Merck
  • Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway.

Urotensin II inhibits doxorubicin-induced human umbilical vein endothelial cell death by modulating ATF expression and via the ERK and Akt pathway.

PloS one (2014-10-01)
Yen-Ling Chen, Yi-Ting Tsai, Chung-Yi Lee, Chien-Hsing Lee, Chung-Yi Chen, Chi-Ming Liu, Jin-Jer Chen, Shih-Hurng Loh, Chien-Sung Tsai
RESUMO

Regulation of the homeostasis of vascular endothelium is critical for the processes of vascular remodeling and angiogenesis under physiological and pathological conditions. Urotensin II (U-II), a potent vasoactive peptide, participates in vascular and myocardial remodeling after injury. We investigated the protective effect of U-II on doxorubicin (DOX)-induced apoptosis in cultured human umbilical vein endothelial cells (HUVECs) and the potential mechanisms involved in this process. Cultured HUVECs were treated with vehicle, DOX (1 µM), U-II, or U-II plus DOX. Apoptosis was evaluated by DNA strand break level with TdT-mediated dUTP nick-end labeling (TUNEL) staining. Western blot analysis was employed to determine the related protein expression and flow cytometry assay was used to determine the TUNEL positive cells. U-II reduced the quantity of cleaved caspase-3 and cytosol cytochrome c and increased Bcl-2 expression, which results in protecting HUVECs from DOX-induced apoptosis. U-II induced Activating transcription factor 3 (ATF3) at both mRNA and protein levels in U-II-treated cells. Knockdown of ATF3 with ATF3 siRNA significantly reduced ATF3 protein levels and U-II protective effect under DOX-treated condition. U-II downregulated p53 expression in DOX-induced HUVECs apoptosis, and it rapidly activated extracellular signal-regulated protein kinase (ERK) and Akt. The DOX induced change of p53 was not affected by U-II antagonist (urantide) under ATF-3 knockdown. The inhibitory effect of U-II on DOX-increased apoptosis was attenuated by inhibitors of ERK (U0126) and PI3K/Akt (LY294002). Our observations provide evidence that U-II protects HUVECs from DOX-induced apoptosis. ERK-Akt phosphorylation, ATF3 activation, and p53 downregulation may play a signal-transduction role in this process.

MATERIAIS
Número do produto
Marca
Descrição do produto

Sigma-Aldrich
Hidrocortisona, BioReagent, suitable for cell culture
Sigma-Aldrich
hEGF, EGF, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture
Sigma-Aldrich
Hidrocortisona, γ-irradiated, powder, BioXtra, suitable for cell culture
Sigma-Aldrich
Hidrocortisona, ≥98% (HPLC)
Sigma-Aldrich
EGF human, Animal-component free, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Sigma-Aldrich
Fator de crescimento epidérmico, EGF, recombinant, expressed in Escherichia coli, >97% (SDS-PAGE)
Sigma-Aldrich
FGF-2 human, recombinant, expressed in E. coli, ≥95% (SDS-PAGE), ≥95% (HPLC)
Supelco
Hidrocortisona, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Hidrocortisona, meets USP testing specifications
Sigma-Aldrich
FGF-2 human, recombinant, expressed in insect cells, ≥85% (SDS-PAGE)
Hidrocortisona, European Pharmacopoeia (EP) Reference Standard
Hidrocortisona, European Pharmacopoeia (EP) Reference Standard
Hidrocortisona, British Pharmacopoeia (BP) Assay Standard
Sigma-Aldrich
MISSION® esiRNA, targeting human ATF3 (1)
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Atf3